CSTONE PHARMA-B (02616) rose more than 6% in afternoon trading. At the time of writing, the stock was up 6.73%, trading at HK$10.15 with a turnover of HK$120 million. The movement follows recent news where CStone Pharma announced positive preliminary efficacy data from the I/II phase trial of CS2009 as a monotherapy for lung cancer at the end of last month. The company plans to initiate the first global multi-center Phase III clinical trial for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer, and small cell lung cancer. China Merchants Securities International issued a research report significantly raising the target price for CStone Pharma by 131.5%, from HK$7.3 to HK$16.9, while maintaining an "Add" rating. The institution increased its asset valuation for CS2009, noting that although there is uncertainty in the asset's future clinical development, it believes the company's management has a clear R&D strategy and vision. There is also potential for deep collaboration with major overseas pharmaceutical companies. CS2009, a trispecific antibody, is expected to break through as a promising candidate.